Pure Global
NCT06133101

Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

Marialena Mouzaki·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
Standard Soy Milk
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Marialena Mouzaki
Funder
Children's Hospital Medical Center, Cincinnati
Timeline & enrollment
Phase
Phase 2
Start date
Nov 01, 2023
End date
Jun 01, 2026
Enrollment
44 participants
Primary outcome

Change in liver disease severity

Summary

A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk
 consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators
 hypothesize that the daily consumption of soy isoflavones found in the soy milk will be
 beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do
 not expect any adverse endocrine or metabolomic effects from the consumption of soy
 isoflavones.

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06133101
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06133101 through Pure Global AI's free database. This Phase 2 trial is sponsored by Marialena Mouzaki and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.